Macrae Sandy 4

What Happened

• Sandy Macrae, President, CEO and Director of Sangamo Therapeutics, had 22,543 restricted stock units (RSUs) vest on May 25, 2026. To satisfy mandatory tax withholding, 12,613 of those vested shares were surrendered (reported as a disposition) to the company at $0.17 per share, for a reported total of $2,198. Footnote clarifies the issuer's closing price that day was $0.1743/share, and the surrender is a required tax-withholding action—not an open-market sale.

Key Details

• Transaction date: May 25, 2026; Form 4 filed May 27, 2026 (timely filing within the usual 2‑business‑day window).
• Reported price/value: $0.17 per share per the Form 4, total $2,198; footnote lists closing price $0.1743/share used for withholding.
• Shares impacted: 22,543 RSU shares vested on May 25; 12,613 were surrendered for tax withholding, leaving 9,930 vested shares delivered to Macrae.
• Future vesting: An additional 246,094 shares from the same RSU grant remain unvested and will vest in seven equal quarterly installments, subject to continuous service and potential acceleration under the 2018 EIP.
• Footnote: The withholding is deemed a disposition for reporting purposes (transaction code F) and does not represent a discretionary open‑market sale by the insider.

Context

• This was a routine tax-withholding disposition tied to RSU vesting (a common practice often called a "sell-to-cover" or surrender for withholding). Such transactions are administrative and don't necessarily signal the insider's view of the company's prospects.